Advanced imaging, like 4D-flow CMR, aids in understanding PA remodeling in different PH subtypes, offering non-invasive differentiation. PAH patients exhibit distinct PA flow characteristics, ...

In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...

Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved ...

In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...

Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...

Tectonic Therapeutic reported positive Phase 1b trial results for TX45, showing improved hemodynamics in PH-HFpEF patients without serious adverse events. Despite the positive results, the company ...

With pulmonary arterial hypertension (PAH) being a disease of a progressive nature, noninvasive parameters are sought to help follow the patients' course and detect deterioration. The 6-minute walk ...

Individualized treatment and close monitoring are essential for pregnant women with pulmonary hypertension due to high maternal and fetal risks. Prognosis in pulmonary hypertension varies with ...

Tectonic Therapeutic, Inc. announced positive interim results from its Phase 1b clinical trial of TX45, a long-acting Fc-relaxin fusion protein, which demonstrated significant improvements in left ...